Complement as a Biomarker for Systemic Lupus Erythematosus

Masahiro Ayano, Takahiko Horiuchi

Research output: Contribution to journalReview articlepeer-review

5 Citations (Scopus)


Systemic lupus erythematosus (SLE) is a disease of immune complex deposition; therefore, complement plays a vital role in the pathogenesis of SLE. In general, complement levels in blood and complement deposition in histological tests are used for the management of SLE. Thus, the evaluation of complement status can be useful in the diagnosis of SLE, assessment of disease activity, and prediction of treatment response and prognosis. In addition, novel complement biomarkers, such as split products and cell-bound complement activation products, are considered to be more sensitive than traditional complement markers, such as serum C3 and C4 levels and total complement activity (CH50), which become more widely used. In this review, we report the complement testing in the management of SLE over the last decade and summarize their utility.

Original languageEnglish
Article number367
Issue number2
Publication statusPublished - Feb 2023

All Science Journal Classification (ASJC) codes

  • Biochemistry
  • Molecular Biology


Dive into the research topics of 'Complement as a Biomarker for Systemic Lupus Erythematosus'. Together they form a unique fingerprint.

Cite this